- Report
- March 2024
- 175 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Report
- February 2024
- 112 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2024
- 150 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Clinical Trials
- April 2024
- 120 Pages
Global
From €1922EUR$2,000USD£1,648GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1442EUR$1,500USD£1,236GBP
- Report
- March 2024
- 238 Pages
Global
From €7641EUR$7,950USD£6,553GBP
- Report
- April 2023
- 175 Pages
Global
From €5670EUR$5,899USD£4,862GBP
- Report
- November 2020
- 241 Pages
Global
From €3061EUR$3,185USD£2,625GBP
€4373EUR$4,550USD£3,750GBP
- Report
- October 2023
- 270 Pages
China
From €3845EUR$4,000USD£3,297GBP
- Report
- October 2023
- 135 Pages
China
From €1730EUR$1,800USD£1,484GBP
Cefepime is an antibiotic used to treat a variety of bacterial infections. It belongs to the fourth-generation cephalosporin class of antibiotics, which are used to treat infections caused by Gram-negative bacteria. Cefepime is often used to treat infections that are resistant to other antibiotics, such as those caused by Pseudomonas aeruginosa. It is also used to treat urinary tract infections, skin and soft tissue infections, and pneumonia. Cefepime is available in both intravenous and oral formulations.
Cefepime is a widely used antibiotic in the treatment of bacterial infections. It is often used in combination with other antibiotics to treat infections that are resistant to other antibiotics. It is also used in the treatment of infections caused by multidrug-resistant organisms. Cefepime is generally well tolerated and has a low risk of adverse effects.
Some companies in the Cefepime market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Sanofi. Show Less Read more
